Oral News and Research

RSS

Janssen signs license agreement with PATH for early development HIV-1 medicine rilpivirine

Janssen R&D Ireland announced today it has signed a license agreement with PATH for the early development of the human immunodeficiency virus type 1 medicine rilpivirine in a long-acting injection (depot formulation) as potential pre-exposure prophylaxis against HIV infection.

25 Sep 2013

Johns Hopkins receives $7.3M contract to reduce ventilator-associated pneumonia

The Johns Hopkins Armstrong Institute for Patient Safety and Quality has been awarded a three-year, $7.3 million contract from the Agency for Healthcare Research & Quality to bring its proven checklist for reducing ventilator-associated pneumonia — the most lethal of all hospital-acquired infections — to hospitals nationwide.

25 Sep 2013

Researchers blame HPV for increased number of young adults with oropharyngeal cancer

The human papillomavirus (HPV) may be to blame for the alarming increase of young adults with oropharyngeal cancer, according to researchers from Henry Ford Hospital in Detroit.

25 Sep 2013

Quartette tablets now available in U.S. for prevention of pregnancy

Teva Women's Health, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd., today announced that the recently approved Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets are now available via prescription in the U.S. for the prevention of pregnancy.

24 Sep 2013

Abbvie, Galapagos Ink Up To $405M CF Collaboration

...

24 Sep 2013

Dental caries show ‘unexpected’ relationship with head and neck cancer

People with dental caries have a reduced risk for developing head and neck squamous cell carcinoma, a large case-control study has found.

24 Sep 2013

PRSA-NCC presents PRR with 2013 Thoth Best in Show Award

The Public Relations Society of America, National Capital Chapter, presented PRR with its 2013 Thoth Best in Show Award Wednesday, the evening's top honor for Washington D.C.-area industry professionals.

21 Sep 2013

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Janssen Pharmaceuticals, Inc. announced today a newly published, pooled analysis of the Phase III EINSTEIN trial program, showing XARELTO (rivaroxaban) is as effective as the standard of care in reducing the risk of deep vein thrombosis and pulmonary embolism in people with symptomatic DVT or PE, while reducing the incidence of major bleeding by 46 percent.

21 Sep 2013

Specialty asthma care no benefit to adherence in underserved children

Results of a study of underserved children with asthma in the USA suggest that they may be losing out on the benefits of specialty care.

20 Sep 2013

Swallow therapy combats post-radiotherapy dysphagia

Swallowing exercises can help to minimize the risk for dysphagia in patients undergoing radiotherapy for head and neck cancer, a case study suggests.

20 Sep 2013

Hormone replacement therapy formulations may cause different risks for stroke, heart attack

Post-menopausal women whose doctors prescribe hormone replacement therapy for severe hot flashes and other menopause symptoms may want to consider taking low doses of Food and Drug Administration-approved bioidentical forms of estrogen or getting their hormones via a transdermal patch.

20 Sep 2013

Orbeshield Earns Soligenix Up To $26.3M From BARDA

...

19 Sep 2013

ASTRO to honor Atlanta resident and cancer survivor with 2013 Survivor Circle Award

The American Society for Radiation Oncology has selected Atlanta resident and cancer survivor Sherri Graves Smith to receive the 2013 Survivor Circle Award.

19 Sep 2013

Postpartum sexuality: an interview with Dr Sari van Anders, University of Michigan, Ann Arbor

Research on postpartum seems to have focused on birth mothers for good reason: women (and, of course, some transmen) are the ones who carry a pregnancy and give birth, and the postpartum is conceptualized as “following birth”.

19 Sep 2013

Federal judge passes consent order against Shamrock Medical for distributing mislabeled drugs

The U.S. Food and Drug Administration announced today that federal judge Algenon L. Marbley of the Southern District of Ohio has approved a consent decree of permanent injunction against Shamrock Medical Solutions Group, LLC, of Lewis Center, Ohio, and four of its corporate officers and employees for continued drug manufacturing and labeling violations that resulted in the distribution of mislabeled drugs.

19 Sep 2013

Overactivity of EGFR protein leads to heightened cancer growth and chemotherapy resistance

Overactivity of a protein that normally cues cells to divide sabotages the body-s natural cellular recycling process, leading to heightened cancer growth and chemotherapy resistance, UT Southwestern Medical Center researchers have found.

19 Sep 2013

Nanodiamonds could be used to promote bone growth and durability of dental implants

UCLA researchers have discovered that diamonds on a much, much smaller scale than those used in jewelry could be used to promote bone growth and the durability of dental implants.

19 Sep 2013

Researchers discover new way to combat HIV-1 infection

Current drug treatments for HIV work well to keep patients from developing AIDS, but no one has found a way to entirely eliminate the virus from the human body, so patients continue to require lifelong treatment to prevent them from developing AIDS.

19 Sep 2013

Doctoral thesis sheds light on phenomenon of war rape in DRC

Rape in war cannot be addressed in isolation. It is deeply embedded in both the local context and that of global proportions. This is one of the conclusions made in a doctoral thesis about eastern Democratic Republic of Congo presented at Uppsala University, Sweden, on 19th September.

18 Sep 2013

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Boehringer Ingelheim and Eli Lilly and Company today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin* at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) which will take place in Barcelona, from 23 – 27 September. The presentations will add to the already existing body of data on safety and efficacy of these two compounds.

18 Sep 2013

Oral News and Research

Janssen signs license agreement with PATH for early development HIV-1 medicine rilpivirine

Johns Hopkins receives $7.3M contract to reduce ventilator-associated pneumonia

Researchers blame HPV for increased number of young adults with oropharyngeal cancer

Quartette tablets now available in U.S. for prevention of pregnancy

Abbvie, Galapagos Ink Up To $405M CF Collaboration

Dental caries show ‘unexpected’ relationship with head and neck cancer

PRSA-NCC presents PRR with 2013 Thoth Best in Show Award

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Specialty asthma care no benefit to adherence in underserved children

Swallow therapy combats post-radiotherapy dysphagia

Hormone replacement therapy formulations may cause different risks for stroke, heart attack

Orbeshield Earns Soligenix Up To $26.3M From BARDA

ASTRO to honor Atlanta resident and cancer survivor with 2013 Survivor Circle Award

Postpartum sexuality: an interview with Dr Sari van Anders, University of Michigan, Ann Arbor

Federal judge passes consent order against Shamrock Medical for distributing mislabeled drugs

Overactivity of EGFR protein leads to heightened cancer growth and chemotherapy resistance

Nanodiamonds could be used to promote bone growth and durability of dental implants

Researchers discover new way to combat HIV-1 infection

Doctoral thesis sheds light on phenomenon of war rape in DRC

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News